Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2003-02-21
2009-08-11
Rao, Manjunath N (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S008100, C514S021800, C530S399000, C530S350000, C530S397000
Reexamination Certificate
active
07572763
ABSTRACT:
The present invention relates to the use of proteins comprising at least one follistatin domain to modulate the level or activity of growth and differentiation factor-8 (GDF-8). More particularly, the invention relates to the use of proteins comprising at least one follistatin domain, excluding follistatin itself, for treating disorders that are related to modulation of the level or activity of GDF-8. The invention is useful for treating muscular diseases and disorders, particularly those in which an increase in muscle tissue would be therapeutically beneficial. The invention is also useful for treating diseases and disorders related to metabolism, adipose tissue, and bone degeneration.
REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 5639638 (1997-06-01), Wozney et al.
patent: 5700911 (1997-12-01), Wozney et al.
patent: 5723125 (1998-03-01), Chang et al.
patent: 5756457 (1998-05-01), Wang et al.
patent: 5827733 (1998-10-01), Lee et al.
patent: 5914234 (1999-06-01), Lee et al.
patent: 5942420 (1999-08-01), Holtzman
patent: 5994618 (1999-11-01), Lee et al.
patent: 6004937 (1999-12-01), Wood et al.
patent: 6096506 (2000-08-01), Lee et al.
patent: 6340668 (2002-01-01), Celeste et al.
patent: 6368597 (2002-04-01), Strassmann et al.
patent: 6369201 (2002-04-01), Barker et al.
patent: 6372454 (2002-04-01), Duan et al.
patent: 6437111 (2002-08-01), Wozney et al.
patent: 6537966 (2003-03-01), Duan et al.
patent: 6548644 (2003-04-01), Pettit
patent: 6656475 (2003-12-01), Lee et al.
patent: 6696260 (2004-02-01), Lee et al.
patent: 6835544 (2004-12-01), Mathews et al.
patent: 6994857 (2006-02-01), Rosen et al.
patent: 2002/0150577 (2002-10-01), Lee et al.
patent: 2003/0104406 (2003-06-01), Wolfman et al.
patent: 2003/0138422 (2003-07-01), Aghajanian et al.
patent: 2003/0162714 (2003-08-01), Hill et al.
patent: 2003/0180306 (2003-09-01), Hill et al.
patent: 2004/0077053 (2004-04-01), Lee et al.
patent: 2004/0138118 (2004-07-01), Wolfman et al.
patent: 2004/0142382 (2004-07-01), Veldman et al.
patent: 2004/0181033 (2004-09-01), Han et al.
patent: 2004/0223966 (2004-11-01), Wolfman et al.
patent: 2005/0043232 (2005-02-01), Lee et al.
patent: 2005/0106154 (2005-05-01), Hill et al.
patent: 1 061 940 (2003-12-01), None
patent: 1 444 985 (2004-08-01), None
patent: WO 94/21681 (1994-09-01), None
patent: WO 94-26892 (1994-11-01), None
patent: WO 96-01845 (1996-01-01), None
patent: WO98/33887 (1998-08-01), None
patent: WO98/35019 (1998-08-01), None
patent: WO 99/24058 (1999-05-01), None
patent: WO 99/45949 (1999-09-01), None
patent: WO 99/56768 (1999-11-01), None
patent: WO 00/11163 (2000-03-01), None
patent: WO 00/43781 (2000-07-01), None
patent: WO 01/64888 (2001-09-01), None
patent: WO 02/09641 (2002-02-01), None
patent: WO 02/068650 (2002-09-01), None
patent: WO 03/027248 (2003-04-01), None
patent: WO 04-058988 (2004-07-01), None
Schneyer et al 2001.Mol. And Cell Endocrinology 180:33-38.
Gosselink et al 1999. Eur Respir J. 13:449-454.
Keutmann et al 2004. Mol. Endocrinology 18:228-240.
U.S. Appl. No. 10/253,532, filed Sep. 25, 2002.
International Search Report, mailed Feb. 4, 2003, based on PCT/US02/30452.
International Search Report, mailed Feb. 25, 2003, based on PCT/US02/03467.
Hamrick et al. “Bone Mineral Content and Density in the Humerus of Adult Myostatin-Deficient Mice”Calcified Tissue International, 71(1):63-68 (2002).
Hayette et al. “FLRG (Follistatin-Related Ggene), A New Target of Chromosomal Rearrangement in Malignant Blood Disorders”Onconogene, 16:2949-2954 (1998).
Lee et al. “Regulation of Myostatin Activity and Muscle Growth”PNAS, 98(16):9306-9311 (2001).
Maguer-Satta et al. “During Hematopoiesis, Expression of FLRG, a Novel Activin A Ligand, is regulated by TGF-β”Exp. Hematol., 29:301-308 (2001).
McPherron et al. “Double Muscling in Cattle Due to Mutations in the Myostatin Gene”PNAS, 94:12457-12461 (1997).
Schneyer et al. “Follistatin-Related Protein (FSRP): A New Member of the Follistatin Gene Family”Mol. Cell. Endocrinol., 180:33-38 (2001).
Thies et al. “GDF-8 Propeptide Binds to GDF-8 and Antagonizes Biological Activity by Inhibiting GDF-8 Receptor Binding”Growth Factors, 18:251-259 (2000).
Tsuchida et al. “Identification and Characterization of a Novel Follistatin-like Protein as a Binding Protein for the TGF-β Family”J. Biol. Chem., 275:40788-40796 (2000).
Tsuchida et al. “Intracellular and Extracellular Control of Activin Function by Novel Regulatory Molecules”Mol. Cell. Endocrin., 180:25-31 (2001).
Zhu et al. “Dominant Negative Myostatin Produces Hypertrophy without Hyperplasia in Muscle”FEBS Letters, 474(1):71-75 (2000).
Zwusen et al. “Characterization of a Rat C6Glioma-Secreted Follistain-Related Protein (FRP)”Eur. J. Biochem., 225:937-946 (1994).
Alliel et al., “Testican, a Multidomain Testicular Proteoglycan Resembling Modulators of Cell Social Behaviour,”Eur. J. Biochem. 214:347-350 (1993).
Amthor et al., “The Expression and Regulation of Follistatin and a Follistatin-like Gene During Avian Somite Compartmentalization and Myogenesis,”Dev. Biol.178:343-362 (1996).
Ashmore et al., “Comparative Aspects of Muscle Fiber Types in Fetuses of the Normal and ‘Double-Muscled’ Cattle,”Growth38:501-506 (1974).
Bakker et al., Duchenne and Becker Muscular Dystrophies. In Diagnostic Criteria for Neuromuscular Disorders, 2nd eds., Emery, ed., Royal Society of Medicine Press, 1998; pp 1-4.
Bartholin et al., “FLRG, an Activin-Binding Protein, is a New Target of TGFβ Transcription Activation Through Smad Proteins,”Oncogene20:5409-5419 (2001).
Bogdanovich et al., “Functional Improvement of Dystrophic Muscle by Myostatin Blockade,”Nature420:418-421 (2002).
Brown et al., “Physicochemical Activation of Recombinant Latent Transforming Growth Factor-Beta's 1, 2, and 3,”Growth Factors3:35-43 (1990).
Bulfield et al., “X Chromosome-Linked Muscular Dystrophy (mdx) in the Mouse,”Proc. Natl. Acad. Sci. U.S.A.81:1189-1192 (1984).
Derynck et al., “Human Transforming Growth Factor-β Complementary DNA Sequence and Expression in Normal and Transformed Cells,”Nature316:701-705 (1985).
Emery, “The Muscular Dystrophies,”Lancet359:687-695 (2002).
Escolar et al., “Pharmacologic and Genetic Therapy for Childhood Muscular Dystrophies,”Current Neurology and Neuroscience Reports1:168-174 (2001).
Gamer et al., “A Novel BMP Expressed in Developing Mouse Limb, Spinal Cord, and Tail Bud Is a Potent Mesoderm Inducer inXenopusEmbryos,”Dev. Biol.208:222-232 (1999).
Gentry et al., “The Pro Domain of Pre-Pro-Transforming Growth Factor β1 When Independently Expressed Is a Functional Binding Protein for the Mature Growth Factor,”Biochemistry29:6851-6857 (1990).
Gillis, “Multivariate Evaluation of the Functional Recovery Obtained by the Overexpression of Utrophin in Skeletal Muscles of themdxMouse,”Neuromuscular Disorders12:S90-S94 (2002).
Girard et al., “Modulation of Endothelial Cell Adhesion by Hevin, an Acidic Protein Associated with High Endothelial Venules,”J. Biol. Chem. 271:4511-4517 (1996).
Gonzalez-Cadavid et al., “Organization of the Human Myostatin Gene and Expression in Healthy Men and HIV-Infected Men With Muscle Wasting,”Proc. Natl. Acad. Sci. U.S.A., 95:14938-14943 (1998).
Grady et al., “Skeletal and Cardiac Myopathies in Mice Lacking Utrophin and Dystrophin: A Model for Duchenne Muscular Dystrophy,”Cell90:729-738 (1997).
Hamrick et al., “Femoral Morphology and Cross-Sectional Geometry of Adult Myostatin-Deficient Mice,”Bone27:343-349 (2000).
Hill et al., “Regulation of Myostatin in Vivo by Growth and Differentiation Factor-Associated Serum Protein-1: A Novel Protein with Protease Inhibitor and Follistatin Domains,”Mol. Endocrinol. 17:1144-1154 (200
Hill Jennifer J.
Wolfman Neil M.
Finnegan Henderson Farabow Garrett & Dunner LLP
Rao Manjunath N
Shafer Shulamith H
Wyeth
LandOfFree
Follistatin domain containing proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Follistatin domain containing proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Follistatin domain containing proteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4105800